NCT00401947 is a Phase 2 clinical trial of ACH-0137171 in HCV Infection, sponsored by Alexion Pharmaceuticals, Inc..

Who is sponsoring NCT00401947?

NCT00401947 is sponsored by Alexion Pharmaceuticals, Inc..

What drugs are being tested in NCT00401947?

Interventions in NCT00401947: ACH-0137171.

What condition does NCT00401947 study?

NCT00401947 studies HCV Infection.

Is NCT00401947 still recruiting?

NCT00401947 is currently terminated. Last updated 15 September 2022.

Last reviewed 2022-09-15 · How we verify

NCT00401947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

Terminated Phase 2 Last updated 15 September 2022

What this trial tests

Phase 2 trial testing ACH-0137171 in HCV Infection in 30 participants. Terminated before completion.

Timeline

30 November 2006

31 March 2007

Quick facts

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	30 November 2006
Estimated completion	31 March 2007
Sites	9 locations across Netherlands, United States, Germany

Drugs / interventions tested

ACH-0137171 — full drug profile →

Conditions studied

HCV Infection — all drugs for HCV Infection →

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 60, any sex, with HCV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple doses of ACH-0137171 in participants with chronic hepatitis C virus (HCV) infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HCV Infection

Currently open trials in the same condition.

NCT05992077 — Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia · NA · active not recruiting
NCT05534633 — APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies · NA · active not recruiting

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00401947 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
Last refreshed: 15 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00401947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing